Key facts
- Notable investors include Innovation Factory (Hamilton), Novatio Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for 3io Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for 3io Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About 3io Therapeutics
Operator of a biotechnology company intended for the development and commercialization of the next generation of viral immunotherapies for cancer. The company engages in developing novel viral immunotherapy based on bovine herpesvirus type for hard-to-treat cancers and helps boost checkpoint inhibitor efficacy, immuno-stimulating mechanism of action, monotherapy with minimal genetic engineering, anti-tumor efficacy, enabling clients to improve treatment responses and outcomes for cancers including those with KRAS-mutations.
- Sector
- Healthcare
- HQ
- Toronto, Canada
- Founded
- 2020
- Employees
- 3
- Website
- 3iotherapeutics.com/
- Ownership
- Privately Held (backing)
3io Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 3io Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 3io Therapeutics in its N-PORT filings yet. We sweep new filings monthly.